Technology Viral RNA Modification Technique To Create Attenuated Live Vaccines For Respiratory Syncytial Virus (RSV) and Other NNS RNA Viruses A method to attenuate RSV and other NNS RNA viruses by reducing m6A modifications on their RNA. This approach enhances genetic stability, ensures sufficient attenuation, triggers higher immune responses, retains…
Technology Q11: a Highly Homogeneous Multivalent and Single-component Vaccine Adjuvating Platform There is a limited choice in clinically approved adjuvants for vaccine development. Current solutions are themselves immunogenic, causing injection site swelling and reactions. The inventors developed a 15 amino acid…
News Patent of the Week: Enhancing Vaccine Efficiency Researchers at the Pritzker School of Molecular Engineering at the University of Chicago developed a new platform technology for improving the efficiency of vaccines. Jeffrey Hubbell, Eugene Bell Professor in...
News Patent of the Week: Creating a Temperature-Stable Vaccine Platform Researchers have developed a novel vaccine platform with fewer side-effects and shelf-stability, which addresses the significant challenge of distributing vaccines to developing countries.
Technology A Next-Generation mRNA Vaccine Platform For Enhancing T-Cell Responses And Improving Antiviral And Antitumor Immunity Next-generation mRNA vaccine platform uses a lipid-polymer hybrid nanoparticle to boost stability, immune cell uptake, and T cell responses, leading to stronger and longer-lasting protection against viruses and cancer while…
Technology Nanovaccine That Activates The NLRP3 Inflammasome & Enhances Tumor Specific Activation Of Anti-Cancer Immunity A major attention of vaccine adjuvant development has been focused on development of robust antibody-mediated protection against pathogens. However, such adjuvants have failed to elicit a robust T-cell mediated protection…
Technology Enhanced Vaccine Efficiency via an Antigen Targeting, Immune Stimulating Co-polymer Vaccine efficacy is limited due to the inability to deliver in-tact antigens to antigen presenting (APC) dendritic cells (DCs) while simultaneously activating the cells in a non-toxic fashion. Adjuvants have…
News Patent of the Week: Increased Safety and Improved Protection of Vaccines Researchers, including Aaron Esser-Kahn, an associate professor at UChicago’s Pritzker School of Molecular Engineering, have filed a patent application for a novel additive that limits undesirable vaccine-related side effects. Many...
News Patent of the Week: In Search of a Universal Flu Vaccine University of Chicago researchers, including Patrick Wilson, PhD, professor of medicine, UChicago Biological Sciences Division, have filed a patent for a panel of antibodies that neutralize a range of influenza...
Technology New Platform For Targeted Immunomodulation And Vaccine Development There have been significant research efforts to develop effective vaccines that elicit a strong and durable T cell response against intracellular pathogens and cancer. A popular strategy has been to…
Technology Lymphangiogenesis For Therapeutic Immunomodulation A vaccine platform that uses engineered lymphangiogenesis factors and antigens to stimulate lymphatic endothelial cells, creating strong, long-lasting immune memory or tolerance with fewer side effects than traditional vaccines The…
Technology Tumor-Specific Cancer Vaccine Adjuvant Formulation Many cancer vaccines fail due to insufficient CD8+ T cell targeting. To save patient lives, oncologists need tumor-specific vaccines that increase CD8+ T cell response. The inventors developed and validated…
